acknowledges the company's lack of expertise in drug discovery. He says there will now be a "top-to-bottom review" of the company's operations, and that it will hire the skills it will need. In this endeavour, Celera's greatest asset may be its cash reserve of almost $1 billion, accrued when investors' hopes for the company peaked two years ago.
Venter's departure leaves the door open for White to recruit a new leader for Celera with the right experience in drug discovery and development. The company has reorganized to focus on the systematic identification of proteins that are expressed differently in diseased tissue and normal tissue, and which may represent good drug targets.
But lists of poorly characterized potential drug targets have little value in themselves. In November, Celera bought Axys Pharmaceuticals, a small-molecule drug development company based in San Francisco, whose capabilities in pharmacology, assay development and structural biology will help it to select the most promising drug targets.
Samuel Broder, Celera's chief medical officer, says this results in a "unique combination of proteomics, combinatorial chemistry and computational biology" that will give Celera an edge in drug discovery. The company says it has already identified a couple of promising compounds for the possible treatment of autoimmune disease and thrombosis.
But sceptics point out that neither Celera nor Axys has an established track record in this area. "Celera is one of perhaps 500 to 1,000 raw start-up companies interested in drug discovery that is in a rudimentary and undefined state," says William Haseltine, a former colleague and long-time critic of Venter. Haseltine is chief executive of Human Genome Sciences, another Rockville-based biotechnology company. He adds that any small company "that thinks it can outdo large companies in chemical-based drug discovery" is labouring under a major misconception.
Venter's departure was not entirely unexpected, and had little impact on Celera's stock. It held steady at a value of around $23 during the week of the announcement -far below its March 2000 high-water mark of $247.
Celera's sister company, Applied Biosystems, has suffered from declining sales of its sequencing machines and reagents, which it attributes mainly to lower-than-expected demand from genomics researchers.
As for Venter himself, the normally voluble bête noire of US molecular biology was unavailable for comment, reportedly sunning himself on his racing yacht in the Caribbean.
According to Broder, Venter is "returning to his first love: science". There's no word yet on when or where Venter will resurface, but as Broder puts it: "There are always creative surprises whenever Craig is involved." 
